Pregnancy Care in Ahmedabad — End-to-End Maternal Care

Visit frequency follows current WHO 2016 antenatal care recommendations (a minimum of 8 contacts) and is intensified for higher-risk pregnancies:

1. Pre-conception or first contact (ideally before 12 weeks) — confirmation of pregnancy, dating ultrasound, history, examination, baseline blood tests, first-trimester counselling, folic acid review.
2. 11 to 13+6 weeks — combined first-trimester screening (NT scan with PAPP-A and free β-hCG), early anatomy survey.
3. 16 weeks — review of first-trimester results, MSAFP or quad screen if applicable, supplement and exercise counselling.
4. 18 to 22 weeks — anomaly scan (ISUOG-aligned), maternal review.
5. 24 to 28 weeks — glucose tolerance testing for gestational diabetes, anti-D prophylaxis (where indicated), repeat anaemia screen, fetal growth assessment.
6. 30 to 32 weeks — growth scan, position assessment, birth planning conversation.
7. 34 to 36 weeks — growth and presentation review, Group B Streptococcus testing where applicable, anti-D top-up where indicated.
8. 37 to 41 weeks — weekly review including BP, fetal movement, presentation, cervix assessment where indicated, induction or expectant management decision.

Higher-risk pregnancies (gestational diabetes, hypertensive disorders, growth restriction, twins, prior caesarean, advanced maternal age, IVF, ART, autoimmune conditions, thrombophilia, hypothyroidism) have additional structured visits and scans.

• First-trimester bloods — full blood count, blood group with Rh and antibody screen, HIV, hepatitis B, hepatitis C, syphilis (VDRL/TPHA), rubella IgG, varicella status, TSH, vitamin D, ferritin, HbA1c or fasting glucose where risk warrants, urine culture.
• Combined first-trimester screening — NT scan combined with serum PAPP-A and free β-hCG between 11+0 and 13+6 weeks. Where indicated and available, non-invasive prenatal testing (NIPT) is offered as a more sensitive option, with counselling about its scope and limits.
• Anomaly scan — performed between 18 and 22 weeks following ISUOG anatomical survey protocols.
• Fetal echocardiography — offered where cardiac risk is elevated (family history, maternal diabetes, IVF/ICSI conception, NT above threshold, congenital cardiac anomaly suspected on routine anatomy scan).
• Glucose tolerance test — 75-g OGTT at 24 to 28 weeks per current IADPSG / WHO criteria; earlier testing in patients with high baseline risk.
• Growth scans — at 28 to 32 weeks and 34 to 36 weeks, more frequently where indicated.
• Doppler studies — uterine artery, umbilical artery, MCA, ductus venosus as clinically indicated.
• Cervical length assessment — in patients with prior preterm birth, short cervix on routine scan, or other risk factors.

Investigation is paced — not bulk-ordered. Each test has a specific question it is asked to answer.

Gestational diabetes mellitus (GDM)

GDM is glucose intolerance first identified in pregnancy. Diagnosis follows IADPSG / WHO thresholds on 75-g OGTT. Management is stepwise — lifestyle and medical nutrition therapy first, with metformin or insulin added when targets are not met. Postpartum 6-week OGTT is mandatory because GDM identifies a population at long-term type 2 risk. The conversation about lifelong cardiometabolic follow-up starts during pregnancy, not after delivery.

Hypertensive disorders of pregnancy

Includes chronic hypertension, gestational hypertension, pre-eclampsia, and eclampsia. Screening uses BP measurement at every visit, plus a structured first-trimester pre-eclampsia risk assessment combining maternal factors, mean arterial pressure, and where available uterine artery Doppler and PlGF (per FMF and FIGO algorithms).

Patients identified as high-risk for pre-eclampsia are offered low-dose aspirin (75 to 150 mg daily, before 16 weeks where possible) per current ACOG and NICE guidance. Suspected pre-eclampsia is monitored intensively. Severe features (BP ≥160/110, neurological symptoms, abnormal labs, fetal compromise) trigger inpatient management and individualised delivery timing.

Anaemia of pregnancy

Iron-deficiency anaemia is the most common medical condition in pregnancy in our region. Ferritin and CBC are followed serially. Oral iron is first-line; intravenous iron is reserved for inadequate response, intolerance, or short window to delivery. The threshold for IV iron is set deliberately above the minimum so that women are not “just managed” but actually corrected.

Thyroid disease in pregnancy

TSH is checked at first contact and re-checked through pregnancy. Treatment is individualised per current Endocrine Society / ATA guidance. Subclinical and overt hypothyroidism are treated to trimester-specific targets. Hyperthyroidism is co-managed with endocrinology.

Group B Streptococcus

Universal vaginal-rectal swab is offered between 35 and 37 weeks. Intrapartum antibiotic prophylaxis is provided to GBS-positive women and to those with risk factors (preterm labour, prolonged rupture of membranes, intrapartum fever, prior GBS-positive infant) per current ACOG and RCOG guidance.

Twins and higher-order pregnancy

Twin pregnancies are managed more intensively — earlier scans, chorionicity determination at 11 to 14 weeks, growth scans every 2 to 4 weeks depending on chorionicity, screening for twin-to-twin transfusion syndrome in monochorionic-diamniotic pregnancies, and a structured delivery plan. Higher-order pregnancies (triplets and above) are managed in close consultation with a maternal-fetal medicine specialist.

High-risk pregnancy categories

Pregnancies are stratified for risk at first visit and re-stratified at each scan and trimester. Higher-risk categories include:

• Advanced maternal age (≥35 years)
• Pregnancy after IVF / ICSI / donor egg or sperm
• Prior caesarean section (VBAC counselling)
• Prior preterm birth, prior stillbirth, prior severe pre-eclampsia, prior placental abruption
• Chronic medical conditions — diabetes, hypertension, autoimmune disease, thrombophilia, epilepsy, mental illness, cardiac disease, renal disease
• Multiple pregnancy
• Identified fetal anomaly
• Suspected placental dysfunction or growth restriction
• Suspected preterm labour

Each high-risk category has its own surveillance protocol. The patient is told which category applies, why, and what the additional steps involve.

• Folic acid — 400 mcg daily from pre-conception through the first trimester; higher dose (4 to 5 mg) where indicated.
• Iron — supplemented from the second trimester unless ferritin is adequate.
• Calcium — supplementation where dietary intake is low; particularly relevant in pre-eclampsia risk.
• Vitamin D — checked and supplemented to adequacy.
• Iodine — diet is reviewed; salt and seafood sources are common adequate routes; specific supplementation only where intake is inadequate.
• Protein and energy — patients are counselled away from “eating for two” misconceptions and toward steady, varied, adequate intake. Indian diet contexts — vegetarian, lacto-vegetarian, ovo-vegetarian, non-vegetarian — are accommodated individually.
• Caffeine — limited to under 200 mg per day per current evidence.
• Alcohol — avoided.
• Tobacco — cessation supported with referral where appropriate.
• Exercise — 150 minutes of moderate activity per week in uncomplicated pregnancy per ACOG, in absence of obstetric contraindication.
• Sleep — left-lateral sleeping position is encouraged after 28 weeks; sleep disturbance is treated, not dismissed.
• Sexual activity — continued in normal pregnancy unless specific contraindication.
• Travel — air travel safe up to 36 weeks in uncomplicated pregnancy, 32 weeks in twins; insurance review encouraged; movement during long flights.

Recommended pregnancy vaccines per current Indian and international guidance include tetanus-diphtheria (Td or Tdap), influenza (inactivated), COVID-19 per current public-health schedule, and where indicated, hepatitis B, varicella-zoster (post-delivery if non-immune), MMR (post-delivery if non-immune), RSV maternal vaccination (per access and indication). Live vaccines are avoided during pregnancy.

Seek urgent assessment if any of the following occur during pregnancy:

• Reduced or absent fetal movements (especially after 28 weeks)
• Severe or persistent headache, particularly with visual changes
• Persistent upper abdominal pain
• Sudden facial, hand, or leg swelling
• Heavy vaginal bleeding
• Watery vaginal discharge that suggests membrane rupture
• Regular contractions before 37 weeks
• Severe nausea and vomiting with reduced fluid intake
• Persistent itching, particularly on palms and soles (obstetric cholestasis)
• Fever above 38°C
• Calf pain, redness, or swelling
• Chest pain or breathlessness
• Suicidal thoughts or significant anxiety

Patients are encouraged to call rather than wait. False alarms are welcomed.

By 32 to 34 weeks the conversation about mode of delivery is structured around:

• Spontaneous vaginal birth — the default in uncomplicated pregnancy.
• Induction of labour — for post-dates, pre-eclampsia, GDM with poor control, oligohydramnios, growth restriction, prolonged ROM, or maternal request after term per local context. Methods, success rates, and contingencies are explained.
• Planned caesarean — for placenta praevia, breech where ECV declined or unsuccessful, prior classical caesarean, certain medical conditions, or maternal request after structured counselling.
• VBAC (vaginal birth after caesarean) — discussed with a structured success-probability model, monitored intrapartum, with clear criteria for conversion.
• Pain relief — non-pharmacological, nitrous oxide, opioids, and epidural — explained without pressure.
• Birth companion — encouraged through normal labour and delivery in line with hospital policy.

A birth plan is welcomed but framed as preferences rather than guarantees. The conversation is documented and shared with the on-call team.

On admission for labour or planned delivery, the standard pathway includes:

• Confirmation of identity and antenatal records review
• Maternal observations — BP, pulse, temperature, urinalysis
• Fetal assessment — CTG or intermittent auscultation per indication
• Per-vaginal examination only when clinically necessary, with consent
• Cannula sited where needed; bloods sent for cross-match where indicated
• Pain-relief plan confirmed
• Birth partner orientation

Patients are kept informed at each step. The decision-making during labour is shared rather than unilateral wherever feasible.

Routine pregnancy is managed within the general antenatal pathway. When higher-acuity scanning, invasive testing, or detailed fetal evaluation is needed — fetal echocardiography, suspected anomaly, growth restriction with abnormal Doppler, twin pregnancy with potential complications — the fetal-medicine programme is engaged in parallel. The two pathways run in tandem rather than serially. Further detail is at /fetal-medicine/.

• We do not perform unnecessary scans beyond clinical indication.
• We do not commercialise the pregnancy journey — no upsell packages, no “VIP” schemes that distort the clinical pathway.
• We do not encourage routine caesarean for non-medical reasons without structured counselling.
• We do not over-medicate. Minor symptoms are managed with reassurance and non-pharmacological measures where appropriate.
• We do not promise outcomes. Pregnancy is a biological process with variation; what we promise is rigorous, kind care.

• Fetal medicine — /fetal-medicine/
• Postnatal care — /postnatal-care/
• Gynaecology — /gynaecology/
• IVF and fertility — /ivf/
• Female reproductive anatomy — /female-reproductive-anatomy/

• WHO — antenatal care for a positive pregnancy experience (2016)
• FIGO — pregnancy and pre-eclampsia screening
• ACOG — antepartum care, hypertensive disorders, GDM, VBAC
• NICE — antenatal care, hypertension in pregnancy, diabetes in pregnancy, intrapartum care
• RCOG — green-top guidelines across pregnancy conditions
• ISUOG — practice guidelines for first-trimester and mid-trimester scanning
• FMF — first-trimester pre-eclampsia risk assessment
• IADPSG — gestational diabetes diagnostic criteria
• ATA / Endocrine Society — thyroid in pregnancy